Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2838 - Prospective evaluation of the relationship between erlotinib concentration and efficacy in patients with non-small cell lung cancer harboring EGFR-activating mutations.


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Non-Small Cell Lung Cancer


Hirotsugu Kenmotsu


Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380


H. Kenmotsu1, C.K. Imamura2, T. Kawamura1, T. Oyakawa1, S. Omori1, K. Nakashima1, K. Wakuda1, A. Ono1, T. Taira1, T. Naito1, H. Murakami1, N. Yamamoto3, T. Takahashi1, Y. Tanigawara2

Author affiliations

  • 1 Division Of Thoracic Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 2 Department Of Clinical Pharmacokinetics And Pharmacodynamics, Keio University School of Medicine, 1608582 - Tokyo/JP
  • 3 Internal Medhicine, Wakayama Medical University, 641-8509 - Wakayama/JP


Abstract 2838


Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), which has shown improved clinical outcomes in the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions and exon 21 L858R mutations. Previous reports regarding the relationship between erlotinib pharmacokinetics and pharmacodynamics evaluated toxicities but not efficacy. Therefore, to evaluate the relationship between erlotinib exposure and efficacy, we conducted this prospective study.


Erlotinib was orally administered at a dose of 150 mg/body once daily to patients with NSCLC, who were not previously treated with EGFR-TKIs. A series of blood samples were taken at predetermined times on day 1 to calculate the area under the concentration-time curve (AUC). Erlotinib trough concentrartions (Ctrough) at each visit and the level of alpha1-acid glycoprotein (AAG), which is a binding protein of erlotinib in serum, were measured.


Of 70 patients enrolled, 61 had activating EGFR mutations (30 patients with exon 19 deletions and 31 with exon 21 L858R mutations). The AUC was 37.0 μg·h/mL in median (range; 9.7-63.3). Objective response rate and median progression-free survival (PFS) were 72% and 12.4 months in the patients with EGFR-activating mutations. Response was not associated with AUC. There was also no significant difference in PFS between patients with AUC > 37.0 μg·h/mL and ≤ 37.0 μg·h/mL. Ctrough was significantly correlated with the grade of skin rash (p  0.97 g/L, 7.9 months; AAG ≤ 0.97 g/L, 16.8 months, p 


The lack of a relationship between erlotinib exposure and efficacy shows that the approved dose of erlotinib is sufficient to reach the therapeutic range in EGFR-activating mutant NSCLC, even with dose reduction due to toxicities. AAG level can be a prognostic factor for patients with NSCLC harboring EGFR-activating mutations treated with erlotinib.

Clinical trial identification

UMIN000012862 (16-Jan-2014)

Legal entity responsible for the study

Shizuoka Cancer Center




H. Kenmotsu, N. Yamamoto, T. Takahashi: Grants and personal fees from Chugai Pharmaceutical Co, Ltd. C.K. Imamura, Y. Tanigawara: Honoraria from Chugai Pharmaceutical Co, Ltd. T. Kawamura, S. Omori, K. Wakuda, A. Ono, H. Murakami: Personal fees from Chugai Pharmaceutical Co, Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.